Highlights
The global Muscle Spasm Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Muscle Spasm Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Muscle Spasm Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Muscle Spasm Therapy in Construction is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Muscle Spasm Therapy include Amgen, Inc., Eisai Co., Ltd., Novartis International AG, GlaxoSmithKline plc, AstraZeneca plc, Pfizer, Inc. and F. Hoffmann La Roche Ltd., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Muscle Spasm Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Muscle Spasm Therapy.
The Muscle Spasm Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Muscle Spasm Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Muscle Spasm Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Amgen, Inc.
Eisai Co., Ltd.
Novartis International AG
GlaxoSmithKline plc
AstraZeneca plc
Pfizer, Inc.
F. Hoffmann La Roche Ltd.
Segment by Type
Muscular Injury
Spinal Nerve Compression
Sprains and Strains of the Muscle Diabetic Ketoacidosis
Others
Segment by Application
Construction
Fire-Fighting
Sports Apparel
Automotive
Aerospace
Military & Defence
Industrial
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Muscle Spasm Therapy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Muscle Spasm Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Muscular Injury
1.2.3 Spinal Nerve Compression
1.2.4 Sprains and Strains of the Muscle Diabetic Ketoacidosis
1.2.5 Others
1.3 Market by Application
1.3.1 Global Muscle Spasm Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Construction
1.3.3 Fire-Fighting
1.3.4 Sports Apparel
1.3.5 Automotive
1.3.6 Aerospace
1.3.7 Military & Defence
1.3.8 Industrial
1.3.9 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Muscle Spasm Therapy Market Perspective (2018-2029)
2.2 Muscle Spasm Therapy Growth Trends by Region
2.2.1 Global Muscle Spasm Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Muscle Spasm Therapy Historic Market Size by Region (2018-2023)
2.2.3 Muscle Spasm Therapy Forecasted Market Size by Region (2024-2029)
2.3 Muscle Spasm Therapy Market Dynamics
2.3.1 Muscle Spasm Therapy Industry Trends
2.3.2 Muscle Spasm Therapy Market Drivers
2.3.3 Muscle Spasm Therapy Market Challenges
2.3.4 Muscle Spasm Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Muscle Spasm Therapy Players by Revenue
3.1.1 Global Top Muscle Spasm Therapy Players by Revenue (2018-2023)
3.1.2 Global Muscle Spasm Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Muscle Spasm Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Muscle Spasm Therapy Revenue
3.4 Global Muscle Spasm Therapy Market Concentration Ratio
3.4.1 Global Muscle Spasm Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Muscle Spasm Therapy Revenue in 2022
3.5 Muscle Spasm Therapy Key Players Head office and Area Served
3.6 Key Players Muscle Spasm Therapy Product Solution and Service
3.7 Date of Enter into Muscle Spasm Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Muscle Spasm Therapy Breakdown Data by Type
4.1 Global Muscle Spasm Therapy Historic Market Size by Type (2018-2023)
4.2 Global Muscle Spasm Therapy Forecasted Market Size by Type (2024-2029)
5 Muscle Spasm Therapy Breakdown Data by Application
5.1 Global Muscle Spasm Therapy Historic Market Size by Application (2018-2023)
5.2 Global Muscle Spasm Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Muscle Spasm Therapy Market Size (2018-2029)
6.2 North America Muscle Spasm Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Muscle Spasm Therapy Market Size by Country (2018-2023)
6.4 North America Muscle Spasm Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Muscle Spasm Therapy Market Size (2018-2029)
7.2 Europe Muscle Spasm Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Muscle Spasm Therapy Market Size by Country (2018-2023)
7.4 Europe Muscle Spasm Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Muscle Spasm Therapy Market Size (2018-2029)
8.2 Asia-Pacific Muscle Spasm Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Muscle Spasm Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Muscle Spasm Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Muscle Spasm Therapy Market Size (2018-2029)
9.2 Latin America Muscle Spasm Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Muscle Spasm Therapy Market Size by Country (2018-2023)
9.4 Latin America Muscle Spasm Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Muscle Spasm Therapy Market Size (2018-2029)
10.2 Middle East & Africa Muscle Spasm Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Muscle Spasm Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Muscle Spasm Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen, Inc.
11.1.1 Amgen, Inc. Company Detail
11.1.2 Amgen, Inc. Business Overview
11.1.3 Amgen, Inc. Muscle Spasm Therapy Introduction
11.1.4 Amgen, Inc. Revenue in Muscle Spasm Therapy Business (2018-2023)
11.1.5 Amgen, Inc. Recent Development
11.2 Eisai Co., Ltd.
11.2.1 Eisai Co., Ltd. Company Detail
11.2.2 Eisai Co., Ltd. Business Overview
11.2.3 Eisai Co., Ltd. Muscle Spasm Therapy Introduction
11.2.4 Eisai Co., Ltd. Revenue in Muscle Spasm Therapy Business (2018-2023)
11.2.5 Eisai Co., Ltd. Recent Development
11.3 Novartis International AG
11.3.1 Novartis International AG Company Detail
11.3.2 Novartis International AG Business Overview
11.3.3 Novartis International AG Muscle Spasm Therapy Introduction
11.3.4 Novartis International AG Revenue in Muscle Spasm Therapy Business (2018-2023)
11.3.5 Novartis International AG Recent Development
11.4 GlaxoSmithKline plc
11.4.1 GlaxoSmithKline plc Company Detail
11.4.2 GlaxoSmithKline plc Business Overview
11.4.3 GlaxoSmithKline plc Muscle Spasm Therapy Introduction
11.4.4 GlaxoSmithKline plc Revenue in Muscle Spasm Therapy Business (2018-2023)
11.4.5 GlaxoSmithKline plc Recent Development
11.5 AstraZeneca plc
11.5.1 AstraZeneca plc Company Detail
11.5.2 AstraZeneca plc Business Overview
11.5.3 AstraZeneca plc Muscle Spasm Therapy Introduction
11.5.4 AstraZeneca plc Revenue in Muscle Spasm Therapy Business (2018-2023)
11.5.5 AstraZeneca plc Recent Development
11.6 Pfizer, Inc.
11.6.1 Pfizer, Inc. Company Detail
11.6.2 Pfizer, Inc. Business Overview
11.6.3 Pfizer, Inc. Muscle Spasm Therapy Introduction
11.6.4 Pfizer, Inc. Revenue in Muscle Spasm Therapy Business (2018-2023)
11.6.5 Pfizer, Inc. Recent Development
11.7 F. Hoffmann La Roche Ltd.
11.7.1 F. Hoffmann La Roche Ltd. Company Detail
11.7.2 F. Hoffmann La Roche Ltd. Business Overview
11.7.3 F. Hoffmann La Roche Ltd. Muscle Spasm Therapy Introduction
11.7.4 F. Hoffmann La Roche Ltd. Revenue in Muscle Spasm Therapy Business (2018-2023)
11.7.5 F. Hoffmann La Roche Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Amgen, Inc.
Eisai Co., Ltd.
Novartis International AG
GlaxoSmithKline plc
AstraZeneca plc
Pfizer, Inc.
F. Hoffmann La Roche Ltd.
听
听
*If Applicable.
